

**April 15, 2019**  
**Announcement no. 5**

### **Grant of warrants**

Today, and in accordance with the company's Remuneration policy and guidelines for incentive-based remuneration and the authorization in section 18 of the Articles of Association, the Board of Directors of BioPorto A/S ("BioPorto") (Nasdaq: BIOPOR) has decided to exercise part of its authorization by issuing 5,100,000 new warrants to BioPorto's management and certain employees of the group.

The issuance of new warrants will support the company's long-term goals and establish a performance-based remuneration reflecting the company's and its shareholders' interests.

Each warrant grants the holder the right to subscribe for one share in the company. The exercise price is fixed at DKK 3.92 per share. Warrants will be exercisable from April 16, 2021 – April 15, 2024. Within the exercise period, warrants can be exercised within ordinary trading windows.

The program includes conditions on claw-back in case of erroneous financial information and on accelerated vesting in case of e.g. a takeover bid, resolution and business transfer.

Detailed terms of the warrants are to be found in the Articles of Association on [www.bioporto.com](http://www.bioporto.com) under Investor Relations> Governance> Company Articles.

The total number of shares granted, and that the warrant holders will be able to subscribe upon exercise of the warrants, is 5,100,000. The theoretical market value of the allocations of warrants amounts to DKK 5,150,617. The calculation is based on the Black-Scholes formula using an interest rate of -0.604% and the historical volatility of BioPorto A/S' shares of 24 months calculated to 47.32%.

After this grant of warrants the total number of outstanding warrants is 15,032,500 as shown in the table below:

	<b>2016</b>	<b>2017</b>	<b>Jun 2018</b>	<b>Aug 2018</b>	<b>Dec 2018</b>	<b>Apr 2019</b>	<b>Total</b>
	<b>program</b>	<b>program</b>	<b>program</b>	<b>program</b>	<b>program</b>	<b>program</b>	
<b>Number of warrants</b>							
Granted	6,368,696	4,350,000	900,000	4,100,000	2,500,000	5,100,000	23,318,696
Cancelled	3,936,196	4,350,000	0	0	0	0	8,286,196
Outstanding	2,432,500	0	900,000	4,100,000	2,500,000	5,100,000	15,032,500
<b>Specified as follows:</b>							
Corporate Management	910,000	0	900,000	3,700,000	2,500,000	5,100,000	13,110,000
Other employees	1,522,500	0	0	400,000	0	0	1,922,500
Total	2,432,500	0	900,000	4,100,000	2,500,000	5,100,000	15,032,500

**For further information, please contact:**

Thomas Magnussen, Chairman of the Board  
 Ole Larsen, CFO  
 Telephone +45 4529 0000, e-mail [investor@bioporto.com](mailto:investor@bioporto.com)

*About BioPorto*

*BioPorto is an in-vitro diagnostics company that provides healthcare professionals in clinical and research settings a range of diagnostic tests and antibodies. BioPorto has its headquarters in Hellerup, Denmark and is listed on the NASDAQ Copenhagen stock exchange.*